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SUMMARY
Mastocytosis comprises a heterogeneous group of disorders character-
ized by the presence of clonal mast cells (MC) in organs such as skin,
bone marrow (BM), and gastrointestinal tract, among other tissues.
The clonal nature of the disease can be established in most adult
patients by the demonstration of activating KIT mutations in their BM
MC. When highly sensitive techniques capable of identifying cells
present at very low frequencies in a sample are applied, BM MC from
virtually all systemic mastocytosis patients display unique immuno-
phenotypical features, particularly the aberrant expression of CD25.
By contrast, large, multifocal BM MC aggregates (the only World
Health Organization major criterion for systemic mastocytosis) are
absent in a significant proportion of patients fulfilling at least three
minor criteria for systemic mastocytosis, particularly in subjects studied
at early stages of the disease with very low MC burden. Moreover,
recent molecular and immunophenotypical investigations of BM MC
from patients with indolent systemic mastocytosis have revealed a close
association of some biological features (e.g., multilineage involvement
of hematopoiesis by the KIT mutation and an immature mast cell
immunophenotype) with an increased risk for disease progression.
These observations support the fact that, although the current
consensus diagnostic criteria for systemic mastocytosis have been a
major advance for the diagnosis and classification of the disease,
rationale usage of the most sensitive diagnostic techniques available
nowadays is needed to improve the diagnosis, refine the classification,
and reach objective prognostic stratification of adult mastocytosis.
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INTRODUCTION
Despite mast cells (MC) have been long recognized as
leading actors in allergic reactions, they have proven
to play a role in many other immune and nonim-
mune responses. After adequate stimuli, MC synthe-
size and release a wide range of mediators which are
involved in the development of clinical symptoms in
allergic diseases and also in clonal MC disorders.
Because MC are present in virtually all tissues, symp-
toms and physical signs of the release of MC mediators
can involve almost every tissue, particularly the skin,
the gastrointestinal tract, and the cardiovascular system.
The term mastocytosis defines a heterogeneous
group of rare disorders characterized by the presence
of clonal MC in one or multiple organs and tissues.
Overall, mastocytosis is considered as a category of
myeloproliferative neoplasms as per the 2008 World
Health Organization (WHO) [1]; in this classification,
diagnosis of systemic mastocytosis (SM) is mainly based
on a major histopathological criterion – presence of mul-
tifocal dense aggregates of 15 MC in the bone marrow
(BM) and/or other extracutaneous tissues – together
with four minor criteria related to BM MC morphology
(atypical MC in smears or biopsy sections of BM or other
extracutaneous organs), immunophenotypic (CD25+
and/or CD2+ MC) and molecular features (D816V KIT
mutation), and biochemical findings (serum tryptase
levels persistently >20 lg/L) findings. Based on these
criteria and the presence vs. absence of a group of so-
called ‘B’ and ‘C’ findings [1–5], which have been
recently reviewed [6] (Table 1), up to seven categories
of mastocytosis are defined by the current WHO classifi-
cation of the disease: cutaneous mastocytosis (CM), extra-
cutaneous mastocytoma, indolent SM (ISM), aggressive
SM (ASM), SM associated with other clonal hematologi-
cal non-MC-lineage disease (SM-AHNMD), MC leuke-
mia (MCL), and MC sarcoma.
In recent years, diagnostic guidelines, algorithms
and recommendations to facilitate implementation of
the WHO criteria have been proposed and preliminary
descriptions of new provisional subvariants have been
made [3, 7–13]. These new provisional subtypes of
mastocytosis include well-differentiated SM (WDSM)
[5, 14–18] and ISM in the absence of skin lesions
(ISMs)) [19, 20]. In addition, other clonal MC syn-
dromes not fulfilling criteria for SM have been
reported which are generally termed as monoclonal
MC activation syndromes [3, 21] or clonal MC activa-
tion disorders [19, 22].
In practice, the great majority of ISM cases corre-
spond to ISM patients who are typically characterized
by low MC burden (particularly at early stages of the
disease) and ascribed to the good-prognosis category of
Table 1. ‘B’ and ‘C’ findings for the diagnosis of
aggressive systemic mastocytosis
‘B’ findings
Findings associated with disease progression and a variable
increase in MC burden which may be also commonly
observed also in ISM with multilineal KIT mutation, sev-
eral years (usually >5 years) after disease onset
1. –BM biopsy with >30% infiltration by MC (focal,
dense aggregates) by histology (and/or >1% by
flow cytometry).
–Serum total tryptase levels >200 lg/L in the
absence of diffuse bone sclerosis.
–Development of diffuse bone sclerosis.
–Increased serum b2-microglobulin.
–Hypercellular BM with loss of fat cells.
2. –Discrete signs of dysmyelopoiesis in non-MC
lineage cells without substantial cytopenias, and
WHO criteria for MDS or MPN
3. –Organomegaly (palpable hepatomegaly,
splenomegaly and/or lymphadenopathy >2 cm on
CT or US) without impaired organ function
‘C’ findings
Findings associated with impaired organ function
because of MC infiltration (e.g. confirmed by biopsy)
1. –Cytopenia (ANC < 1.0 · 109/L, hemoglobin
<100 g/L and/or platelets <100 · 109/L), because
of BM dysfunction with no obvious other non-MC
haematopoietic malignancy
2. –Hepatomegaly with impaired liver function and/or
ascites
3. –Palpable splenomegaly with hypersplenism
4. –Malabsorption with hypoalbuminemia and weight
loss
5. –Skeletal lesions: large-sized osteolytic lesions and/or
pathological fractures associated with local MC
infiltration (pathological fractures or osteolytic
lesions associated with osteoporosis should not be
considered a C-finding)
6. –Life-threatening organopathy in other organ systems
caused by infiltration of the tissue by neoplastic MC
Source: Modified from reference Escribano et al. [6].
MC, mast cell; ISM, indolent systemic mastocytosis; BM,
bone marrow; WHO, World Health Organization; MDS,
myelodysplastic syndrome; MPN, myeloproliferative neo-
plasm; CT, computerized tomography; US, ultrasound;
ANC, absolute neutrophil count.
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the disease. In adults, diagnosis of ISM is suspected on
the basis of the presence of either mastocytosis in the
skin (MIS) and in patients without MIS, anaphylaxis,
and other severe symptoms (e.g., cardiovascular) sug-
gesting MC activation, usually in association with a
mild increase in serum tryptase levels. By contrast,
extremely high serum tryptase levels together with the
presence of C-findings are strongly suggestive of ASM.
Interestingly, a significant proportion of ASM patients
have a long history of an underlying and frequently
misdiagnosed MIS, which can precede by years the
onset of C-findings. In addition, some ISM patients
experience disease progression, particularly those who
show elevated serum b2-microglobulin levels and
D816V KIT mutation involving hematopoietic cells
other than MC, including lymphoid and/or myeloid
cells [4]; interestingly, multilineage involvement of
hematopoiesis by the D816V KIT mutation is systemati-
cally detected in ‘de novo’ ASM patients. Altogether,
these observations suggest that ASM and at least some
ISM cases might actually represent two different stages
of the same disease in which progression from an indo-
lent to an aggressive phase is strongly associated with
multilineal mutation of KIT. It should be noted that,
during the very early stages of ISM, there is neither a
detectable proliferation nor a significant accumulation
of MC in organs/tissues, which makes early accurate
diagnosis of the disease a challenge.
In recent years, the utility of the WHO classifica-
tion for the diagnosis and classification of mastocytosis
has been prospectively evaluated in two independent
studies which included 59 [23] and 133 patients [5].
Both studies provide evidence about the existence of
some false negative cases when the WHO criteria for
SM are strictly used. In addition, some well-recognized
categories of the disease, for example, ISMs) [19, 20]
and WDSM [5, 14–18], are not specifically considered
in the current version of the WHO classification.
Here, we review the most relevant aspects of MC
biology, particularly those related to c-kit signaling and
the clinical manifestations of MC disorders, as well as
the methodological approaches to be applied for an objec-
tive and reproducible diagnosis and classification of SM.
MAST CELL BIOLOGY AND KIT MUTATIONS
Mast cells originate from pluripotential BM-derived
hematopoietic precursors which migrate as immature
cells through the blood stream. From the blood, MC
home mainly into body surface tissues such as the
skin, the airways, and the gastrointestinal tract, where
they become fully differentiated. The stem cell factor
(SCF), the ligand for the tyrosine kinase receptor c-kit
[24], plays a critical role in the proliferation, matura-
tion, and survival of MC [25], in combination with
several other cytokines and growth factors such as IL-
4, IL-6, IL-9, IL-10, IL-12, IL-15, IL-18, nerve growth
factor (NGF), thrombopoietin, and transforming
growth factor (TGF)-beta [26–29, 29–33].
C-kit (CD117) is a type III receptor tyrosine kinase
encoded by the human homolog of the proto-onco-
gene KIT, whose ligand is the SCF; SCF acts as a
growth factor that dimerizes KIT molecules inducing
its tyrosine kinase activity [25]. In humans, the KIT
gene is coded, in the pericentromeric region of the
long-arm of chromosome 4, at chromosome 4q12 [34],
adjacent to the highly homologous PDGFRA gene [35].
Mutations in the KIT tyrosine kinase domain have
been reported in the great majority of SM patients
(>90%) when molecular studies are performed in
highly purified MC [16]. D816V is by far the most fre-
quent mutation; however, other less common muta-
tions have also been identified (reviewed in reference
[36]) mainly in ISM lacking skin lesions [16, 20]
which is of special relevance for the diagnosis of this
subtype of SM. In addition, other rather infrequent
KIT mutations have been described in adults which
are localized at the extracellular domain (two cases of
familial mastocytosis with a deletion of codon 419 of
KIT [37] and the K509I KIT mutation [38], respec-
tively), at the transmembrane domain (a case of
WDSM with the F522C KIT mutation [14] and a case
of familial mastocytosis with the A533D KIT mutation [39])
and at the juxtamembrane domain (a case of ASM
with the V559I KIT mutation [40] and both a case of
MCL [41] and a case of ISMs) (A. Garcia-Montero,
unpublished data) with the V560G KIT mutation. Fur-
thermore, other oncogenic mutations have been
reported in SM, which involve the TET2 (TET onco-
gene family member 2) [42] and N-RAS [43] genes,
and their significance in the pathogenesis of the dis-
ease still remains unknown.
Mast cells play a key role in inflammation and they
are the major effector cell in allergic reactions includ-
ing anaphylaxis. A wide variety of stimuli can trigger
activation of MC during inflammation as well as in
 2012 Blackwell Publishing Ltd, Int. Jnl. Lab. Hem. 2012, 34, 445–460
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allergic and nonallergic diseases, and release of MC
mediators. The most relevant triggers according to
REMA’s experience and literature review (see refer-
ences [44–48]) are shown in Table 2. The release of
MC mediators can be elicited through the cross-link-
ing of high-affinity Fc receptors for IgE (FceRI) on the
cytoplasmic membrane of normal/reactive MC [49, 50],
Fcc [51–53], and complement receptors [49, 50],
among other stimuli. MC synthesize and release a
wide variety of preformed or newly generated media-
tors (reviewed in references [54, 55]), which are
responsible of a great part of the symptoms and signs
exhibited by mastocytosis patients (Figure 1). From a
diagnostic perspective, tryptase is the most relevant
MC mediator. Tryptase is a serin-protease produced by
human MC which is mainly derived from the expres-
sion of two genes coded in chromosome 16p13.3:
a-tryptase and b-tryptase[56]. Notewothy, tryptase is
also produced in smaller quantities by blood basophils
[57]. Precursors of both a-tryptase and b-tryptase are
spontaneously released by MC, while fully processed
(mature) b-tryptase is retained by the cells, mainly
inside the secretory granules [58].
DIAGNOSTIC PROCEDURES
IN MASTOCYTOSIS
Diagnosis of mastocytosis is mainly based on the dem-
onstration of abnormal MC according to a combina-
tion of morphological, immunohistochemical, flow
cytometric immunophenotyping, and molecular studies.
Despite the relevance of the presence of multifocal
dense MC aggregates denoted by its inclusion in the
WHO classification as the only major criterion for SM,
it should be emphasized that, at the early stages of
the disease, BM MC burden is very low and, thus,
MC aggregates are frequently absent in these patients.
In such cases, careful evaluation of morphological,
immunophenotypical, and molecular criteria are
particularly mandatory for correct diagnosis and
classification of the disease (Table 3).
Mastocytosis in the skin
Histomorphological examination of skin lesions plays
a major role in the diagnostic work-up of the disease
[3]. Because wide differences in MC distribution have
been described in normal skin depending on the
specific body site investigated [59], careful evaluation
of MC numbers for that particular site vs. those
expected under normal conditions is required for cor-
rect histological evaluation of skin lesions from sub-
jects suspected of mastocytosis.
Stainings for skin sections should include hematox-
ylin and eosin (H&E), Giemsa and also immunohisto-
chemistry for both c-kit and tryptase. Additionally,
immunostaining for CD25 in lesional mastocytosis
skin biopsy specimens has recently emerged as a
promising method to predict systemic involvement in
patients with MIS [60]. Histological criteria for the
diagnosis of MIS include the presence of large MC
aggregates (>15 MC per cluster) or scattered MC
exceeding 20 cells per microscopic high-power (·40)
field (Reviewed in reference [3]).
Peripheral blood analyses
Although peripheral blood cell counts and differential
are usually normal in nonaggressive mastocytosis,
weak to mild eosinophilia can be found in some cases.
By contrast, cytopenia(s) and cytomorphological changes
suggesting dysplasia are frequently present in ASM
and MCL, as well as in SM-AHNMD. In addition, cir-
culating MC are systematically detected in MCL and
at lower percentages, in the majority of ASM cases
when highly sensitive flow cytometry approaches are
used for the detection of cells present at low frequen-
cies in a sample (L. Sanchez-Muñoz, unpublished
observations).
Bone marrow cytomorphology and
immunohistochemistry
Bone marrow is the most appropriate site for screen-
ing systemic involvement in mastocytosis. Because
BM MC are closely attached to the stroma, BM aspira-
tion should be performed firmly and quickly from the
posterior iliac crest with an 8G to11G biopsy needle,
to obtain sufficient numbers of particles to perform
BM smears, followed by a BM biopsy, the length of
the BM cylinder ideally being of 2 cm.
Bone marrow cytomorphology
Bone marrow smears must be stained with at
least toluidine blue (Figure 2, panels B and C) and
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May-Grünwald-Giemsa (MGG) (Figure 2, panels A, D
and E) for cytomomorphological evaluation of MC.
MC can be easily identified in toluidine blue-stained
BM smears as red-purple elements over a blue back-
ground; the toluidine blue stain allows an overall
Table 2. Factors that can evoke the release of MC
mediators in patients with mastocytosis
Physical agents
– Heat (frequent): use mildly warm water for bath or
shower. Do not rub briskly with towel to dry off.
When drying hair, use hair dryer only on warm heat
– Cold (frequent)
– Pressure (frequent): traumas to scalp in patients with
skin lesions in this area. Avoid Darier’s sign (friction
of skin lesions), this procedure can evoke a massive
mast cell mediators release, specially in large lesions
(mastocytomas)
– Exercise (rare)
– Endoscopies (exceptional): panendoscopy,
rectoscopy, colonscopy






– NSAIDs* (frequent) such as aspirin (acetylsalicylic
acid), mefanamic acid, butibufen, diclofenac,
fenbufen, fenilbutazone, flurbiprofen, ibuprofen,
indometacine, ketoprofen, ketorolac,
meclofenamate, metamizole, nabumetone,
naproxen, propifenazone, among other drugs
– Opioids and morphine derivatives (rare) such as
morphine, codeine, buprenorphine, meperidine,
dextromethorphan, dimemorphan, fentanyl,
tramadol, among other drugs
– Alcohol† (rare)
– Muscle relaxants and inductors used in general
anesthesia (rare)
– Local anesthetics‡ (exceptional if amide-derivatives
are used)
– Contrast media (rare)
– Interferon-alpha 2b§ (exceptional)




– Hymenoptera sting (frequent, particularly in ISMs-)





– Infections or fever of any etiology (frequent,
particularly in children)
– Teething in children (frequent)
– Vaccination (rare, except in children with DCM)
Table 2. (Continued)
Source: REMA, specific protocols in risk situations in
patients with mastocytosis, updated 2011.
*The frequency of MC-mediators release related to NSA-
IDs in patients from the REMA is 2% in children and
14% in adults [47].
†The frequency of MC-mediators release symptoms
triggered by alcohol in patients from the REMA is <1%
(REMA, unpublished data).
Among 73 adult patients from the REMA who
underwent general anaesthesia, three suffered severe
MC-mediators release symptoms (two cardiorrespiratory
arrests, and one coagulopathy with hypovolemic shock),
the specific protocols in risk situations in mastocytosis
were not followed in such three cases (REMA, unpub-
lished); regarding pediatric mastocytosis, 17 children
underwent general anaesthesia, and no severe mast-cell
mediators release episodes were reported (REMA,
unpublished data).
‡No MC-mediators related symptoms were recorded in
850 BM biopsies and 1,235 cutaneous biopsies performed
in patients from the REMA between 1984 and 2006
using adequate premedication (REMA, unpublished
data); in eight of these cases who had previous history of
anaphylaxis induced by stress, the BM biopsies were per-
formed in the ICU with premedication, local anaesthesia
and sedation.
§No MC-mediators related symptoms were reported in
23 cases from the REMA who underwent interferon
therapy (REMA, unpublished data); in all of these cases,
antimediator premedication was used according to the
REMA0s specific protocols, and the three initial doses
were administered at an ICU.
–Only one case has been reported so far (J. Sheik, Beth
Israel Hospital, Harvard Medical School, personal
communication, September 2002).
**It has been seen in one patient from the REMA
(REMA, unpublished data).
††The frequency of pregnancies with a worsening of
MC-mediators symptoms during pregnancy ranges from
22% [48] to 45% [44].
MC, mast cell; GI, gastrointestinal; NSAIDs, non-steroidal
antiinflammatory drugs; REMA, Spanish Network on
Mastocytosis; ISMs-, indolent systemic mastocytosis in
the absence of skin lesions; DCM, diffuse cutaneous
mastocytosis; BM, bone marrow; ICU, Intensive Care
Unit.
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estimation of the degree of BM infiltration by MC
and, therefore, also an estimation of the amount of
sample needed to be further processed for immuno-
phenotyping and molecular analyses. Interestingly,
BM MC aggregates (major WHO criterion for SM) are
frequently detected in BM smears containing enough
BM particles [5]. In turn, MGG stain allows a better
cytomorphological characterization of MC as well as
the identification of eosinophilia, dysplastic features,
and other morphological features suspicious of a coex-
isting hematological malignancy. It should be empha-
sized that for correct cytomorphological evaluation of
MC, this should be performed outside BM particles.
The most commonly described MC atypias in SM are
spindle-shaped MC, eccentric and oval nucleus, hypo-
granulation, abnormal granule distribution, and gran-
ule fusion phenomena; however, in some cases,
round or poligonal MC coexist with fusiform shapes
or they even predominate [5]. Such atypical MC mor-
phological features can also be seen in disease condi-
tions other than mastocytosis, for example, a subset of
hypereosinophylic syndromes (HES) with the FIP1L1-
PDGFRA fusion gene, elevated serum tryptase, and
CD25+ MC lacking somatic KIT mutations [12]. In a
subgroup of patients, particularly in ASM and MCL
cases showing higher degree of BM infiltration, MC
also show immature cytological features such as a
wide size heterogeneity, multilobed nuclei (promasto-
cytes), or a poor-differentiated morphology (meta-
chromatic blasts) [5, 8]. In contrast, among WDSM
cases, BM MC typically exhibit a mature appearance,
an increased size, and a round shape, with round
nucleus and a fully granulated cytoplasm with rela-
tively frequent degranulation phenomena (vacuoles)
[18]. However, these findings are associated but not
fully specific of WDSM and they must be considered
in the overall clinical, immunophenotypical, and
molecular setting of the patient, to diagnose or rule
out WDSM.
In MCL, which is a rare variant of mastocytosis
characterized by a rapidly progressive disease with
multiorgan involvement and a very poor pronosis,
highly atypical MC (e.g., metachromatic blasts
and promastocytes) can be seen in both BM and
peripheral blood smears. Main cytomorphological
characteristics of these MC include the presence of bi-
or polylobed nuclei, a high nuclear-to-cytoplasmic
ratio, smooth chromatin, prominent nucleoli and
usually few scattered metachromatic granules,
which might difficult their identification as MC-line-
age cells.
Bone marrow histopathology
The presence of multifocal, dense aggregates of 15
MC in tissue sections from biopsy specimens from
BM and/or other extracutaneous organs is highly
specific of mastocytosis, and they are constantly
observed in all poor-prognosis categories of the dis-
ease (ASM, MCL, and SM-AHNMD); nevertheless,
around 20% of all ISMs+ cases and up to 35% of
ISMs- lack such aggregates [4, 5, 20], these cases fre-
quently corresponding to patients that show both
lower percentages of BM MC by flow cytometry and
lower serum baseline tryptase levels. This translates
into a lower sensitivity of the WHO major criterion
for the diagnosis of SM at the early stages of the
disease [5].
Figure 1. Main mast cell media-
tors (reviewed in references [54,
55]).
 2012 Blackwell Publishing Ltd, Int. Jnl. Lab. Hem. 2012, 34, 445–460
450 I. ALVAREZ-TWOSE ET AL. CLONAL MAST CELL DISEASES
In c-kit (Figure 2, panels F and G) and/or tryptase-
stained (Figure 2, panels I and J) BM sections, MC
can be easily identified as spindle-shaped or round
cells, or an admixture of both [5]. As for skin sections,
CD25 (Figure 2, panel H) is also a useful immunohis-
tochemical marker to confirm the neoplastic nature of
Table 3. Most relevant laboratory hematology techniques required for the diagnosis and classification of mastocytosis
and their clinical utility
Method Technical issues Information provided Diagnostic utility




Stainings: toluidine blue, MGG,
other (if associated
diseases are suspected)
MC morphology Minor criterion: Abnormal
MC morphology








MC morphology Minor criterion: Abnormal
MC morphology





Sample containing BM particles MC numbers Minor criterion: expression
of CD25 and/or CD2
Monoclonal antibody clones,
fluorochrome reagents
and combinations should be
carefully selected




pattern of MC: Mature
resting vs. activated vs.
immature
Apply specific gating strategies Imunophenotypical
characteristics of other
cell lineages
In cases with very low MC
numbers acquire
enough number of cells






Study of KIT mutations in




to MC vs. multilineal










by HUMARA in women
with KIT mutation-negative
MC
Purify at least MC, neutrophils,
monocytes and lymphocytes
Investigate clonality by the
HUMARA test in women
lacking KIT mutations
Source: Escribano et al. [6].
BM, bone marrow; MC, mast cells; MGG, May-Grünwald-Giemsa; H&E, hematoxylin and eosin; DNA, deoxyribonu-
cleic acid; RNA, ribonucleic acid; PCR, polymerase chain reaction; FACs, fluorescence-activated cells; HUMARA,
human androgen receptor; SM-AHNMD, systemic mastocytosis with an associated clonal haematological non-mast cell
lineage disease.
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MC in cases showing compact MC aggregates [61, 62];
nevertheless, this staining has a more limited utility in
cases lacking MC aggregates in which the distinction
between abnormal MC and CD25-positive T-lympho-
cytes becomes a challenge, and in CD25-negative
WDSM subjects. In addition, expression of CD30 (also
known as Ki-1 antigen) has been reported to be a
potentially useful prognostic marker in mastocytosis
because this marker is strongly expressed by MC from
poor-prognosis categories of mastocytosis (ASM and
MCL), while its expression is missing or low in most
ISM cases [63; 64].
Depending on the number and distribution of MC in
the BM, different histological patterns can be observed
(reviewed in reference [65]. Accordingly, whereas
ASM and MCL cases systematically show a dense, dif-
fuse MC infiltration, ISM may have different patterns
of BM involvement ranging from an increase of inter-
stitial MC without evidence of compact MC aggregates,
to focal, dense MC aggregates with or without a diffuse
component. Interestingly, these focal MC aggregates
are commonly paratrabecular in location, which might
facilitate the frequent development of bone alterations
in patients with ISM. Other relatively common findings






Figure 2. Images of bone marrow (BM) smears (panels
a to e) and BM sections (panels f to j) from several
systemic mastocytosis (SM) patients. (a) High-power
view showing fusiform mast cells (MC) together with
round and oval MC from a case of indolent SM
(ISM). (b) Low-power view showing a marked
increase of atypical MC from an aggressive SM
(ASM) patient. (c) High-power view showing two
spindle-shaped MC. (d) High-power view showing
round, fully granulated MC from a case of well-dif-
ferentiated SM (WDSM). (e) High-power view show-
ing morphologically poor-differentiated MC, some of
which display two nuclei (promastocytes) from a
case of ASM. (f) Low-power view showing a perivas-
cular infiltrate of MC from a case of ISM. (g) Low-
power view showing a large lymphoid aggregate
admixed with MC from a case of ISM. (h) Low-
power view showing CD25-positive MC from a case
of ISM. (i) High-power view showing round, fully
granulated, tryptase-positive MC from a case of
WDSM. (j) Low-power view showing a dense, diffuse
MC infiltration from a case of ASM.
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diffuse eosinophilia and lymphoid aggregates usually
surrounding or admixed with MC clusters. The pres-
ence of such lymphoid aggregates has been found in
44% of all SM cases in our series (L. Escribano, unpub-
lished data) and they contain both mature T and B cells
[66], but its significance remains still unknown. By
contrast, pronounced BM fibrosis and/or osteosclerosis
are more frequently associated with poor-prognosis cat-
egories with high MC burden.
Multiparameter flow cytometry immunophenotypical
analysis of mast cells
Flow cytometry is the preferred method for the evalu-
ation of CD25 and CD2 expression on BM MC from
subjects suspected of mastocytosis, particularly among
cases with low MC numbers. Because of its great sen-
sitivity, flow cytometry immunophenotypical analysis
of BM MC is currently considered the gold standard
for the identification of aberrant MC. MC from BM
samples from both normal subjects and mastocytosis
patients can be specifically identified and accurately
enumerated using multiparameter flow cytometry
based on their unique light scatter properties, dim
CD45 and strong CD117 expression [67] (Figure 3).
The technical aspects as well as the critical parameters
related to MC identification, enumeration, and immu-
nophenotyping have been extensively reviewed else-
where [13, 68–71].
In addition, flow cytometric immunophenotype of
BM MC from SM patients has been extensively inves-
tigated [69, 72–78]. In contrast to normal MC, MC
from mastocytosis aberrantly express high levels of the
low affinity IL-2 receptor a-chain (CD25) [13, 74, 79],
except in WDSM [5, 14, 17, 18]; in turn, expression
of CD2 is not detected in a variable percentage of SM
cases [17, 80, 81]. Based on these findings, it has
recently been proved that CD25 expression is a more
reliable diagnostic criterion for SM other than WDSM
compared with the current CD25 and/or CD2 expres-
sion, proposed by the WHO [81]. Apart from the aber-
rant expression of CD25 and CD2, BM MC from SM
display other immunophenotypical alterations which
have been extensively described and reviewed in the
literature. Noteworthy, clonal MC from WDSM
typically display overexpression of cytoplasmic
enzymes such as tryptase and carboxypeptidase,
despite they do not show aberrant expression of CD25
and CD2 [17, 80]. Distinct diagnostic categories of SM
are associated with unique immunophenotypic fea-
tures which also reflect the multilineage involvement
of BM hematopoiesis [13, 17, 67, 69–74, 76, 82–85].
Accordingly, three different maturation-associated
immunophenotypic profiles have been recently identi-
fied in BM MC from patients with SM [17] which cor-
relate with prognostic and molecular subtypes of the
disease (Figure 3): i) an activated MC phenotype, typ-
ical of the majority of ISM patients, which is charac-
terized by aberrant expression of CD25 and CD2
together with an abnormally increased expression of
the CD63, CD69, and CD203c proteins and both the
CD64 high-affinity FcIgG receptor and the HLA-DR
MHC class II molecule; ii) a mature resting MC phe-
notype, detected in WDSM, which consists of lack of
expression of both CD25 and CD2, a normal profile
for activation-associated markers, strong expression of
CD117 and FceRI; and iii) an immature immunophe-
notypic profile associated with the poor-prognosis cat-
egories of SM, defined by the aberrant expression of
CD25 usually in the absence of CD2, associated with
decreased expression of maturation-associated markers
(e.g., CD117, FceRI) and increased positivity for
CD123, HLA-DQ, and HLA-DR.
Molecular assays
Detection of KIT mutations
Multiple molecular methods have been used to specif-
ically detect the D816V KIT mutation in SM patients
[16, 86–93]. Reverse transcriptase (RT) polymerase
chain reaction (PCR) assays (mRNA/cDNA-based
methods) [86, 88, 92] are very sensitive for the detec-
tion of the KIT mutation in MC admixed with other
cells in the sample at rather low frequencies (e.g.,
BM, blood and spleen), because MC together with a
small subset of basophils and NK-cells are the only
mature hematopoietic cells expressing KIT mRNA
within these samples. Among the genomic (g)DNA-
based methods [16, 86–88, 90, 92, 93], the most
straight forward and simple approach would be those
based in direct sequencing of the mutated DNA locus
[86], but they have very low sensitivity because the
D816V KIT mutation is usually heterozygous and
mutated MC are mixed with huge amounts of other
(ususally nonmutated) hematopoietic (e.g., BM,
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blood, spleen) or epithelial (skin) cells carrying
wild-type KIT. An improved sensitivity has been
reached either by enhancing mutated allele frequen-
cies using digestion steps by specific restriction endo-
nucleases and PCR amplification [86, 91] or by using
specific probes that selectively block amplification of
the wild-type sequence [87]. The later PNA-mediated
wild-type blocking method has the advantage of
allowing detection of the D816V KIT mutation as well
as other rare KIT mutations involving the TK2 regula-
tory domain at codons 815–819 [16, 87]. Other
gDNA-based assays using allele-specific competitive
blockers of the mutated sequences and traditional [89,
90] or quantitative (q)PCR [93] assays also have been
shown to be associated with a very good sensitivity
(<1% or <0.03%, respectively).
Independently of the method used for the KIT
mutation assay, all recent studies on large series of
SM patients have confirmed that D816V KIT mutation
is as frequent in ISM as in ASM [16, 91], with marked
differences in the reported frequencies (range: approx-
imately 80% to approximately 100%) depending on
whether the study was performed in whole BM sam-
ples [91] or in highly purified BM MC [16]. Such
studies have ruled out previous assumptions about
the potential association of the D816V KIT mutation
with the more severe forms of SM (for review see [36]).
Interestingly, we have recently shown that, while
in most ISM cases (73%) the D816V KIT mutation is
restricted to MC, most ASM cases (approximately
98%) carry the KIT mutation in other myeloid and
even lymphoid cell compartments [16]. In addition,
multilineage involvement of hematopoietic cells by
the KIT mutation has also been associated with a
shorter progression-free survival and a worse prognosis
of the disease [4].
Different approaches have been applied to detect
KIT mutations in enriched or purified cell compart-
ments, namely microdissection of archived formalin-
fixed paraffin-embedded BM or skin biopsies [87, 94, 95],
and both immunomagnetic [88, 92] and/or fluores-
cence-activated cell sorting [4, 16, 88] of BM and
blood samples. Currently, in SM cases carrying the
KIT mutation in BM MC, the REMA recommends to
perform the KIT mutation assays in at least one highly
purified population (>97%) of myeloid cells (e.g., BM
monocytes and/or maturing neutrophils) and a popu-







Figure 3. Mast cell identification by flow cytometry (black dots) based on light scatter parameters and on the expres-
sion of CD45 and CD117 (Panels a and b). Overlayed representative immunophenotypic profiles of mast cells from
healthy adults (green dots), indolent systemic mastocytosis (red dots), aggressive systemic mastocytosis (orange
dots) and well-differentiated systemic mastocytosis (blue dots). Data sets representative of each group of subjects
were fused using Infinicyt software (Cytognos SL, Salamanca, Spain) and presented together. The squared dots
represent medians of each data set (Panels c to f).
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CD19+ cells), apart from MC [4, 5]. Of note, it is also
important to rule out cross-contamination of the puri-
fied cell populations by mutated MC, because molecu-
lar methods associated with a very high sensitivity
(<1%) could lead to false positive results whenever
low proportions of mutated MC are present in the
sample containing the purified non-MC population.
As virtually all mature myeloid and lymphoid hema-
topoietic cells do not express the c-kit receptor, only
those methods targeting gDNA [16, 86–90, 93] are
informative for the detection of the presence of the
KIT mutations in mature non-MC hematopoietic cells.
Nevertheless, it should be noted that in SM with mul-
tilineal involvement by the D816V KIT somatic muta-
tion, the disease emerges from early pluripotent
mutated stem cells that coexist with normal stem
cells, and consequently, each hematopoietic popula-
tion (e.g. the monocytes) typically consists of a mix-
ture at different proportions of mutated and
nonmutated cells [96]. Thus, the selected method
should have enough sensitivity to detect relatively
low numbers of mutated cells. In line with this, some
new gDNA-based methods have been described which
are associated with a good sensitivity (<0.03%) and
quantitative (qPCR) estimation of the percentage of
mutated allele dosage [93] in whole peripheral blood
(PB) samples from aleukemic SM patients.
Detection of mast cell clonality
For those rare SM cases which lack KIT mutations
(e.g., most WDSM and some ISMs)), MC clonality
can be confirmed in women through the analysis of
the pattern of inactivation of polymorphic genes
coded in the human chromosome X (e.g., PCR-based
human androgen receptor allele – HUMARA – assay)
[97, 98]. Such assays exploit the random pattern of
inactivation of chromosome X in individual hemato-
poietic stem cells. However, it should be emphasized
that also the HUMARA test must be performed in
gDNA obtained from highly purified (>90%) MC,
using gDNA obtained from, for example, total BM or
PB, as a control [20]. Because most WDSM patients
are women, the HUMARA assay can be applied in the
vast majority of patients with this rare variant of the
disease, being an invaluable tool to confirm the clonal
origin of BM MC and the systemic nature of the dis-
ease [5]. Despite the overall utility of these tech-
niques, they are typically not available in many




The presence of total serum tryptase levels persistently
>20 lg/L is one of the minor diagnostic WHO criteria
for SM. The tryptase test recommended for such mea-
surements in routine laboratory diagnostics is a fluoro-
immunoenzyme assay which detects both the a and
the b tryptase subunits, to yield total serum tryptase
levels (CAP, Phadia Diagnostics, Uppsala, Sweden). In
mastocytosis patients, a correlation between serum
total tryptase levels (sBt) and BM involvement has
been resported [10]. Similarly, sBt levels have also
been associated with different categories of the disease
[99–101] (reviewed in references [99, 100, 102]). Fur-
thermore, elevated tryptase levels are also found in
patients with diffuse bone sclerosis [4, 5, 103], chronic
urticaria [104], clonal myeloid malignancies [9, 11,
12, 105], and advanced kidney disease [106], among
other disorders. To increase the sensitivity of sBt in
SM, it has been recently proposed to lower the 20 lg/L
sBt cut-off [107], in line with our own experience
and data.
Most interestingly, recent data based on a series of
74 patients with ISM who have been prospectively
followed up for a median of close to 8 years show that
those patients who experience progressively increased
in sBt levels over time more likely show disease pro-
gression, while in those who have stable sBt levels,
the disease is kept under an indolent controlled form
(Matito A, unpublished data).
Serum b2-microglobulin and LDH
In a previous prospective study carried out in a large
series of adult ISM cases, we reported that apart from
the presence of multilineal D816V KIT mutation, the
detection of increased serum b2-microglobulin levels
at diagnosis was an independent predictor of transfor-
mation into a more aggressive form of the disease [4].
More recently, it has been reported that the combina-
tion of increased b2-microglobulin and decreased LDH
levels was closely linked to ASM patients, while
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coexistence of both parameters was only found in a
minority of ISM cases [5].
DISEASE MONITORING AND FOLLOW-UP
Disease monitoring in nonaggressive cases should
include a complete clinical and physical work-up
together with a routine peripheral blood count and
differential, routine biochemistry, sBt and b2-micro-
globulin. In addition, imaging studies including
abdominal ultrasonography and/or computed tomog-
raphy scan must be periodically performed (e.g., every
2 years) in cases with multilineal KIT mutations.
Regarding the bone, dual energy X-ray absorptiom-
etry should be performed every 1.5–2 years as a part
of therapy response assessment in cases with bone
mass loss under treatment, whereas every 4–5 years
in patients with normal bone density at diagnosis,
unless additional risk factors for bone mass loss are
present (e.g., menopausia or chronic therapy with
corticosteroids). Skeletal X-ray survey and/or mag-
netic resonance imaging should be only performed
during follow-up in selected patients who develop
bone pain or clinical/laboratory data suggesting dis-
ease progression; in these later cases, a new BM study
must be also performed.
CONCLUSION
Major advances have been made in the last decades in
the understanding of MC disorders, leading to well-
defined consensus diagnostic criteria for mastocytosis.
These criteria include several disease features which
are directly related to the neoplastic nature of MC
(e.g., the cytological, immunohistochemical, immuno-
phenotypic and molecular characteristics of MC),
together with findings that indirectly reflect an esti-
mation of the increased MC burden (e.g., elevated
serum tryptase levels). However, more recent data
indicate that despite the great clinical utility of the
current WHO diagnostic criteria for SM, their role for
the diagnosis of new variants of the disease specifi-
cally not recognized in the WHO classification (e.g.,
WDSM) or SM patients who present at very early
stages of the disease with low MC burden is still lim-
ited. Accumulating evidence also suggests a continu-
ous spectrum of disorders with a close relationship
between the progression of ISM into more agressive
forms of the disease and the presence of specific dis-
ease features such as an immature immunophenotypic
profile of MC, multilineal involvement of BM hema-
topoietic cells by the KIT mutation and increased
b2-microglobulin levels at diagnosis. Because of this,
highly sensitive and specific diagnostic procedures
(e.g., multiparameter flow cytometry immunopheno-
typing of BM MC and molecular analysis of the
D816V KIT mutation in highly purified BM MC and
other purified compartments of hematopoietic cells)
should be routinely performed for diagnostic/prognos-
tic purposes in experienced reference centers during
the diagnostic work-up of patients with mastocytosis,
to avoid false negative results and provide a more pre-
cise estimation of the actual prognosis for individual
patients. When these procedures are not available,
evaluation of surrogate markers (e.g., elevated serum
b2-microglobulin levels at diagnosis and monitoring of
sBt levels over time) may contribute to an indirect
estimation of the risk of disease progression. Despite
this, refined criteria for improved prognostic stratifica-
tion of SM are still needed, particularly for cases diag-
nosed at early stages of the disease with very low MC
burden.
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